Director Elizabeth Crain awarded 18,575 RSUs at Core Scientific (CORZ)

Rhea-AI Filing Summary

Core Scientific, Inc. director Elizabeth Crain received a grant of 18,575 shares of common stock as restricted stock units. The award was reported as acquired at a price of $0 per share on February 4, 2026, increasing her directly held beneficial ownership to 65,348 shares.

The RSUs will vest in full on February 3, 2027, if she continues to serve as a non-employee director through that date. Until vesting, the units represent a right to receive shares rather than currently transferable stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CRAIN ELIZABETH

(Last) (First) (Middle)

C/O CORE SCIENTIFIC, INC.

838 WALKER ROAD, SUITE 21-2105

(Street)

DOVER DE 19904

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Core Scientific, Inc./tx [ CORZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		A		18,575(1)	A	$0	65,348	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on February 3, 2027, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date.

	/s/ Todd DuChene, as Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Core Scientific (CORZ) report for Elizabeth Crain?

Core Scientific reported that director Elizabeth Crain received 18,575 restricted stock units of common stock. The award was recorded at a price of $0 per share and brought her total directly held beneficial ownership to 65,348 shares following the transaction.

When do Elizabeth Crain’s Core Scientific (CORZ) RSUs vest?

Elizabeth Crain’s restricted stock units are scheduled to vest in full on February 3, 2027. Vesting is conditioned on her continuing to provide service to Core Scientific as a non-employee director through that date under the terms of the grant.

How many Core Scientific (CORZ) shares does Elizabeth Crain own after this grant?

After the February 4, 2026 grant, Elizabeth Crain beneficially owns 65,348 shares of Core Scientific common stock directly. This total reflects the addition of 18,575 restricted stock units reported as acquired in the Form 4 insider transaction filing.

What type of equity award did Core Scientific (CORZ) give to Elizabeth Crain?

Core Scientific granted Elizabeth Crain a restricted stock unit, or RSU, award covering 18,575 shares of common stock. These RSUs represent a right to receive shares in the future, subject to vesting, rather than immediate delivery of unrestricted stock.

What role does Elizabeth Crain have at Core Scientific (CORZ)?

Elizabeth Crain is identified as a director of Core Scientific and not as an officer or 10% owner. The RSU grant is tied to her service as a non-employee director, with vesting conditioned on her continued service in that board role.